OOIR: Observatory of International Research

Papers

(The H4-Index of Drug Discovery Today is 59. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Advancing drug repurposing research: Trends, collaborative networks, innovation and knowledge leaders	267
Repurposing of parenterally administered active substances used to treat pain both systemically and locally	241
Contents page	178
CIPDB: A biological structure databank for studying cation and π interactions	173
The potential value of 5-androstenediol in countering acute radiation syndrome	149
The recent progress of deep-learning-based in silico prediction of drug combination	142
Next-generation lung-cancer-on-a-chip: Toward personalized therapy, AI, and CRISPR-driven models	137
General aspects of powder rheology applied to pharmaceutical formulations	135
Antibody–drug conjugates: What drives their progress?	125
Computational modeling approaches and regulatory pathways for drug combinations	125
Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy	124
Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases	115
Accelerating the orphan GPCR pipeline: GPR149 as a case study in dual-domain target validation	112
Opportunities and challenges in drug discovery targeting the orphan receptor GPR12	103
Demystifying the potential of inhibitors targeting DNA topoisomerases in unicellular protozoan parasites	103
The global status of bioequivalence trials: a comprehensive clinical trial landscape analysis based on the Trialtrove database	98
Dysbiosis versus diabesity: Pathological signaling and promising therapeutic strategies	97
Generative AI: driving productivity and scientific breakthroughs in pharmaceutical R&D	96
Artificial-intelligence-guided autophagy modulation and nanomedicine design for precision photodynamic cancer therapy	96
Gastroretentive drug delivery systems: A holy grail in oral delivery	94
On-body drug delivery systems: State-of-the-art technologies, clinical application, and future perspectives	93
Models and approaches to comprehend and address glial inflammation following spinal cord injury	90
Bridging data and drug development: Machine learning approaches for next-generation ADMET prediction	90
From promise to progress: the dynamic landscape of glioblastoma immunotherapy	80
A global bibliometric and visualized analysis of bacteria-mediated cancer therapy	79

Redox active or thiol reactive? Optimization of rapid screens to identify less evident nuisance compounds	79
Tubulin targeting agents and their implications in non-cancer disease management	76
Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five	75
Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics	74
MRI assessment of cerebral perfusion in clinical trials	73
Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease	72
The evolution of ethical and legal regulations of drug research	71
Regulatory approvals of therapeutic biologics: continuing progress or plateauing out compared with those of small molecules?	71
Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein	70
Medicinal chemistry aspects of uracil containing dUTPase inhibitors targeting colorectal cancer	70
Engineering virus-like particles for lymph-node targeted cancer immunotherapy: strategies, challenges, and future prospects	69
The main aspects of non-clinical studies required for obtaining marketing authorisation for small molecules and biologics/biopharmaceuticals in the European Union and the United States	69
Global landscape and translational trajectories of flavonoid-based wound-healing research	69
Recent advances towards overcoming the blood–brain barrier	68
Therapeutic strategies targeting ocular vasculopathies: Current advances and emerging challenges	68
Unlocking therapeutic frontiers: harnessing artificial intelligence in drug discovery for neurodegenerative diseases	68
Randomized controlled trials do not always fit the purpose: A science-based response to Venetis and Mol’s editorial on biosimilars of follitropin alfa	67
Translational PK/PD: a retrospective analysis of performance and impact from a drug portfolio	67
Investigating miRNA subfamilies: Can they assist in the early diagnosis of acute myocardial infarction?	66
Systematic review and QSPR analysis of chemical penetration through the nail to inform onychomycosis candidate selection	66
The emerging role of fatty acid binding protein 7 (FABP7) in cancers	66
Steps toward nebulization in-use studies to understand the stability of new biological entities	65
A review on the recent advances of interaction studies of anticancer metal-based drugs with therapeutic targets, DNA and RNAs	65
Gaps between medical biology and AI drug discovery	64
Targeted protein degradation: current molecular targets, localization, and strategies	63
Caught between a ROCK and a hard place: current challenges in structure-based drug design	63
Peptide cheminformatics tools: making computational tasks accessible in peptide drug discovery	62
MTHFD2: A significant mitochondrial metabolic enzyme and a novel target for anticancer therapy	61
Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance	60
Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development	60
Lactose in tablets: Functionality, critical material attributes, applications, modifications and co-processed excipients	59
Embryonic and larval zebrafish models for the discovery of new bioactive compounds against tuberculosis	59
PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?	59
Oral delivery of nucleic acid therapeutics: Challenges, strategies, and opportunities	59